<DOC>
	<DOCNO>NCT01726452</DOCNO>
	<brief_summary>Primary Objective : To evaluate one , two three year survival patient treat resection plus neoadjuvant adjuvant chemotherapy versus resection plus neoadjuvant chemo radiotherapy . Secondary Objective ( ) : To evaluate effect neoadjuvant regimens clinical pathological response rate ( particular relief dysphagia , improvement health relate quality life ( HRQL ) , endoscopic regression , CT-PET evidence tumour response ) , tumour regression grade , node-positivity , post-operative pathology , disease-free survival , time treatment failure , toxicity , post-operative complication Health Related Quality Life ( HRQL ) . Exploratory Objective ( ) : Translational Research : The collection blood tissue sample storage bio bank future research .</brief_summary>
	<brief_title>MAGIC vs. CROSS Upper GI . ICORG 10-14 , V3</brief_title>
	<detailed_description>Indication : Patients cT2-3 N0-1 M0 adenocarcinoma oesophagus junction , base clinical , CT-PET , EUS staging , randomise MAGIC chemotherapy regimen versus CROSS neoadjuvant chemo radiation protocol prior surgery . Patients randomise either Arm A ( MAGIC regimen chemotherapy surgery ) Arm B ( CROSS protocol : chemotherapy radiation therapy surgery per multimodal protocol ) . Eligible patient randomise 1:1 fashion MAGIC regimen CROSS protocol . Exploratory Study- Translational Research : All patient enrol trial , invited consent tissue blood take use future research study . Following consent patient , tissue biopsy tumour and/or normal oesophageal tissue obtain research time biopsied histological diagnosis . In addition , tumour and/or normal tissue also obtain follow surgical resection . Patient blood sample also obtain , treatment . The identification tumour circulate biomarkers increase knowledge molecular mechanism ( ) underlie treatment response oesophageal cancer may facilitate identification biomarkers predict patient response treatment .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Histologically verified adenocarcinoma oesophagus oesophagogastric junction . 2 . CT 18FDGPET EUS patient 3 . Staging laparoscopy perform tumours abdominal oesophagus , junction proximal stomach i.e . AEG II AEG III ( investigator discretion ) 4 . Pretreatment stage cT23 , N01 , M0 5 . No prior abdominal thoracic radiotherapy 6 . Male/female patient age &gt; 18 year . 7. WHO Performance Status 0 , 1 2 8 . ASA III 9 . Completion baseline quality life questionnaire ( EORTC QLQ C30 ) . 10 . Adequate cardiac function . Patients cardiac history cardiology review leave ventricular ejection fraction &gt; 50 % ( determine MUGA scan ECHO ) . 11 . Adequate respiratory function . Patients pulmonary function test complete FEV1 &gt; 1.5L 12 . Adequate bone marrow function : absolute neutrophil count ( ANC ) &gt; 1.5x10^9/l ; white blood cell count &gt; 3x10^9/l ; platelet &gt; 100x10^9/l ; haemoglobin ( Hb ) &gt; 9g/dl ( posttransfusion ) . 13 . Adequate renal function : glomerular filtration rate &gt; 60ml/minute ( calculate measure ) . 14 . Adequate liver function : serum bilirubin &lt; 1.5x ULN ; AST &lt; 2.5x ULN ALP &lt; 3x ULN ( ULN per institutional standard ) 15 . Written informed consent must obtain patient studytrial specific procedure perform . 1 . Tumours squamous histology . 2 . Patients advance inoperable metastatic oesophageal , junctional gastric adenocarcinoma . 3 . Any prior chemotherapy gastrointestinal cancer . 4 . Prior abdominal thoracic radiation . 5 . Clinically significant ( i.e . active ) cardiac disease ( e.g . symptomatic coronary artery disease myocardial infarction within last 12 month . Patients history clinically significant cardiac failure exclude study entry . 6 . Clinical COPD significant obstructive airway disease classify FEV1 &lt; 1.5 L PaO2 le 9kPa room air 7 . Known peripheral neuropathy &gt; Grade 1 ( absence deep tendon reflexes sole neurological abnormality render patient ineligible ) . 8 . Known positive test human immunodeficiency virus ( HIV ) infection , , acute chronic active hepatitis B infection . 9 . Any malignancy within last 5 year ( curatively treat basal cell carcinoma skin and/or situ carcinoma cervix )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>